| 401 |
16247643 | Phosphodiesterase inhibitors in female sexual dysfunction. | 2005 Dec |
2 |
| 402 |
16273417 | Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. | 2005 Dec |
1 |
| 403 |
16273418 | Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. | 2005 Dec |
2 |
| 404 |
16287454 | An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. | 2005 Dec |
1 |
| 405 |
16292559 | Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance. | 2005 Dec |
1 |
| 406 |
16339700 | Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy. | 2005 |
1 |
| 407 |
16378510 | Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. | 2005 |
2 |
| 408 |
16387565 | Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. | 2005 Dec 26 |
1 |
| 409 |
16387566 | Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. | 2005 Dec 26 |
2 |
| 410 |
16422865 | Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. | 2005 May |
1 |
| 411 |
16985896 | PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy. | 2005 |
1 |
| 412 |
14871543 | Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. | 2004 Feb |
3 |
| 413 |
15075013 | Treatment of erectile dysfunction. | 2004 Apr |
1 |
| 414 |
15080987 | Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring. | 2004 May 3 |
3 |
| 415 |
15083994 | Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. | 2004 Mar |
2 |
| 416 |
15093609 | The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. | 2004 Jun |
3 |
| 417 |
15115191 | Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. | 2004 Apr |
4 |
| 418 |
15148932 | [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction]. | 2004 Apr |
2 |
| 419 |
15155143 | Emerging oral drugs for erectile dysfunction. | 2004 May |
2 |
| 420 |
15175637 | Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). | 2004 Oct |
2 |
| 421 |
15183543 | The impact of sildenafil on molecular science and sexual health. | 2004 Jul |
3 |
| 422 |
15194181 | Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. | 2004 Jun 16 |
1 |
| 423 |
15197447 | [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. | 2004 Jul |
1 |
| 424 |
15213306 | Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. | 2004 Jul |
3 |
| 425 |
15223851 | Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. | 2004 Jul-Aug |
1 |
| 426 |
15224127 | Mechanisms of action of PDE5 inhibition in erectile dysfunction. | 2004 Jun |
1 |
| 427 |
15224129 | Potency, selectivity, and consequences of nonselectivity of PDE inhibition. | 2004 Jun |
1 |
| 428 |
15224132 | Implications of PDE4 structure on inhibitor selectivity across PDE families. | 2004 Jun |
2 |
| 429 |
15260511 | Future options for combination therapy in the management of erectile dysfunction in older men. | 2004 |
1 |
| 430 |
15281210 | [Erectile function disorders. Epidemiology, physiology, etiology, diagnosis and therapy]. | 2004 Jun |
1 |
| 431 |
15295092 | Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. | 2004 Oct |
1 |
| 432 |
15295684 | [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]. | 2004 Aug 13 |
1 |
| 433 |
15312980 | Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). | 2004 Nov |
6 |
| 434 |
15322323 | Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. | 2004 |
1 |
| 435 |
15333581 | The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. | 2004 Sep |
1 |
| 436 |
15371988 | The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. | 2004 Sep |
1 |
| 437 |
15464333 | Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. | 2004 Oct 6 |
4 |
| 438 |
15464535 | Sildenafil: emerging cardiovascular indications. | 2004 Oct |
4 |
| 439 |
15466636 | Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. | 2004 Oct 12 |
2 |
| 440 |
15475488 | Influence of sildenafil on gastric sensorimotor function in humans. | 2004 Nov |
1 |
| 441 |
15476742 | Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil. | 2004 Oct 19 |
1 |
| 442 |
15497717 | [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. | 2004 Sep |
1 |
| 443 |
15522526 | Analysis of undeclared synthetic phosphodiesterase-5 inhibitors in dietary supplements and herbal matrices by LC-ESI-MS and LC-UV. | 2004 Nov 15 |
2 |
| 444 |
15537369 | New treatment options for erectile dysfunction in patients with diabetes mellitus. | 2004 |
1 |
| 445 |
15560162 | [Viagra, cialis, impase--which of them, to whom, when and how?]. | 2004 Sep-Oct |
1 |
| 446 |
15881813 | Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. | 2004 Nov |
4 |
| 447 |
21224902 | Pharmacotherapy of sexual dysfunctions : current status. | 2004 Jul |
1 |
| 448 |
12477710 | Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. | 2003 Jan |
2 |
| 449 |
12554648 | PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. | 2003 Feb 3 |
1 |
| 450 |
12614192 | Long-term use of sildenafil. | 2003 Mar |
2 |